Amgen stock posts 2.61% weekly gain; dazodalibep clears Phase 3 goals

Published on 11/14/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock traded at 421.93 euros on Lang & Schwarz late Saturday morning. The company reported positive Phase 3 results for dazodalibep in Sjogren's disease.

Amgen's clinical update and weekly trading

Amgen reported positive Phase 3 results for dazodalibep in Sjogren's disease on November 11.
Both OASIZ-301 dosing regimens met the trial's primary endpoint after 48 weeks.
Patient-reported dryness also improved for the four-week dosing regimen.

Amgen, US0311621009, Illustration mit AI erstellt.

Amgen reported positive Phase 3 results for dazodalibep in Sjogren's disease on Wednesday, November 11. In an announcement carried by Yahoo Finance, the company said both dosing regimens in the OASIZ-301 study met the primary endpoint after 48 weeks.

Dazodalibep clears both endpoints

The trial evaluated dazodalibep in patients with moderate-to-severe Sjogren's disease. Amgen said the 1,500 milligram regimen given every four weeks and the 3,000 milligram regimen given every 12 weeks produced statistically significant reductions in systemic disease activity versus placebo.

The four-week regimen also improved patient-reported dryness, a key secondary endpoint. The results expand Amgen's late-stage autoimmune pipeline, although further development and regulatory steps remain before any potential approval.

Weekly gain remains moderate

Amgen stock traded at 421.93 euros on Lang & Schwarz at 10:45 CET on Saturday, November 14, 0.64% below the Xetra close of Friday, November 13. The Xetra close was 424.65 euros on Friday, compared with 413.85 euros on Friday, November 6, leaving a 2.61% gain for the reporting week.